Clinical trial
Efficacy and Tolerability of Switching to Ziprasidone From Other Antipsychotics
NCT00458211 · Bronx Psychiatric Center, Other · Completed
Key facts
| NCT number | NCT00458211 |
|---|---|
| Title | Efficacy and Tolerability of Switching to Ziprasidone From Other Antipsychotics |
| Official title | Evaluation of Efficacy and Tolerability of Switching to Ziprasidone From Other Antipsychotic Medications |
| Lead sponsor | Bronx Psychiatric Center, Other |
| Collaborators | Pfizer Industry Buffalo Psychiatric Center Rochester Psychiatric Center |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Schizophrenia, Schizoaffective Disorder |
| Intervention type | Drug |
| Interventions | ziprasidone |
| Enrollment | 40 |
| Start date | May 1, 2005 |
| Primary completion | Apr 1, 2008 |
| Completion | Apr 1, 2008 |
| First posted | Apr 10, 2007 |
| Last update posted | May 1, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: